博拓生物12月23日获融资买入666.53万元，融资余额2.95亿元

Group 1 - The core viewpoint of the news highlights the trading performance and financial metrics of Botao Bio, indicating a decrease in net financing and a significant drop in revenue and profit for the company [1][2] Group 2 - On December 23, Botao Bio's stock rose by 0.76% with a trading volume of 59.20 million yuan. The financing buy-in amount was 6.67 million yuan, while the financing repayment was 9.79 million yuan, resulting in a net financing outflow of 3.12 million yuan [1] - As of December 23, the total margin balance for Botao Bio was 296 million yuan, with the financing balance accounting for 4.95% of the circulating market value, indicating a high level compared to the past year [1] - The company has a total of 7,146 shareholders as of September 30, which is an increase of 28% from the previous period. The average circulating shares per person decreased by 21.87% to 20,897 shares [2] - For the period from January to September 2025, Botao Bio reported a revenue of 308 million yuan, a year-on-year decrease of 20.76%, and a net profit attributable to the parent company of 22.26 million yuan, down 75.04% year-on-year [2] - Since its A-share listing, Botao Bio has distributed a total of 798 million yuan in dividends, with 478 million yuan distributed over the past three years [2] - As of September 30, 2025, one of the top ten circulating shareholders, GF Value Core Mixed A, has exited the list [2]